Bicycle therapeutics reports recent business progress and second quarter 2025 financial results

Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today reported financial results for the second quarter ended june 30, 2025, and provided recent corporate updates. “we continue to execute on our strategy, which is grounded in scientific rigor and focused on fulfilling our mission to develop next-generation prec.
BCYC Ratings Summary
BCYC Quant Ranking